Furthermore, while our study demonstrates the therapeutic potential of low-dose Dex in mitigating AngII-induced VSMC phenotypic switching and AAA progression in preclinical models, these findings are derived solely from cellular and animal experiments. Here, AGT is linked to triple-A syndrome.